Process for the preparation of compositions of AT1 receptor antagonist and Angiotensin—(1-7)
We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus. They may also be used in the study and therapy of cardiovascular, renal, reproductive, dermatological, neoplastic, blood and cerebral diseases, and when formulated in controlled release systems, encapsulated or not in cyclodextrins, for use in stent, with a view to modulate the growth of the neointima after catheterization procedures.
1. A process for preparation of a complex containing AT1 receptor antagonist and Ang-(1-7), comprising:
(a) reacting an aqueous solution of losartan salt as the AT1 receptor antagonist compound with Ang-(1-7) at a molar ratio of 1:1 or 2:1 for AT1 receptor antagonist to Ang-(1-7), at room temperature and under protection from light, to prepare the complex; and
(b) vacuum filtrating the complex to recover a pellet of Ang-(1-7) losartanate.
2. The process according to claim 1 further comprising suspending the pellet in aqueous solution and forming an inclusion complex between the Ang-(1-7) losartanate and a cyclodextrin at a molar ratio of 1:1 to 1:10 for Ang-(1-7) losartanate to cyclodextrin.
3. The process according to claim 2 , wherein the cyclodextrin is alpha-cyclodextrin.
4. The process according to claim 2 , wherein the cyclodextrin is beta-cyclodextrin.
5. The process according to claim 2 , wherein the cyclodextrin is gamma-cyclodextrin.
6. The process according to claim 3 further comprising adding at least one amino acid at a molar ratio of 1:1 to 1:10 for Ang-(1-7) losartanate to amino acid.
7. The process according to claim 4 further comprising adding at least one amino acid at a molar ration of 1:1 to 1:10 for Ang-(1-7) losartanate to amino acid.
8. The process according to claim 5 further comprising adding at least one amino acid at a molar ratio of 1:1 to 1:10 for Ang-(1-7) losartanate to amino acid.
9. A method for treatment of hypertension or diabetes mellitus, comprising administration of the Ang-(1-7) losartanate as an inclusion complex with cyclodextrin as defined in claim 2 .
10. A method of using the AT1 receptor antagonist and Ang-(1-7) compound as defined in claim 1 comprising administration of Ang-(1-7) losartanate as an inclusion complex with cyclodextrin for treating of hypertension or diabetes mellitus.
11. A method for treatment of hypertension or diabetes mellitus, comprising administration of the pharmaceutical composition of claim 5 .
12. A method for treatment of hypertension or diabetes mellitus, comprising administration of the pharmaceutical composition of claim 6 .
13. The process according to claim 2 , wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.
14. The process according to claim 1 further comprising suspending the pellet in aqueous solution and adding at least one amino acid at a molar ratio of 1:1 to 1:10 for Ang-(1-7) losartanate to amino acid.
15. The process according to claim 14 further comprising adding a cyclodextrin at a molar ratio of 1:1 to 1:10 for Ang-(1-7) losartanate amino acid to cyclodextrin.
16. The process according to claim 14 , wherein the at least one amino acid is L-arginine.
17. A process for preparation of an inclusion complex containing AT1 receptor antagonist, Ang-(1-7) and cyclodextrin, comprising:
(a) reacting an aqueous solution of losartan salt as the AT1 receptor antagonist compound with Ang-(1-7) at a molar ratio of 1:1 to 2:1 for AT1 receptor antagonist to Ang-(1-7) and
(b) adding cyclodextrin at a molar ratio of 1:1 to 1:10 for Ang-(1-7) losartanate to cyclodextrin to prepare the inclusion complex.
18. The process according to claim 15 , wherein the at least one amino acid is L-arginine.